Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Two Techniques for the SLN Detection in BC Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02032498
Recruitment Status : Unknown
Verified July 2014 by Jules Bordet Institute.
Recruitment status was:  Recruiting
First Posted : January 10, 2014
Last Update Posted : July 24, 2014
Sponsor:
Information provided by (Responsible Party):
Jules Bordet Institute

Brief Summary:

The revision of our data shows that since its introduction in our institution (Jules Bordet Institute) in 1998 (until 2010, the year of the last review of cases), 53 patients underwent neoadjuvant therapy before selective sentinel lymph node dissection followed by conventional axillary dissection.

The analysis of these cases shows that:

  • The lack of demonstration of sentinel lymph nodes observed in 8 cases (6 cN0) is associated in 75% of them with a pN+ status
  • If scintigraphic imaging is "positive" (demonstration of the sentinel lymph nodes: 35 cN0 and 10 cN+), our results appear favorable with a single false negative SLN result (False Negative Rate = 1/20 or 5%).

Therefore we propose additional technique for LN detection by indocyanine green, we hypothesize that the combination of two different injections improves the technique of sentinel lymph node biopsy.


Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Indocyanine Green Phase 2

Detailed Description:

The principal objective of this study is to evaluate the detection rate, the false negative rate and the overall accuracy of the lymphofluoroscopic research of the sentinel lymph nodes after periareolar injections of Indocyanine Green (ICG) in combination and in comparison with our classical intramammary and peritumoral injections of 99mTc-HSA-Nanocolloids in patients with breast cancer. These patients are currently out of the inclusion criteria and still undergo systematically complete axillary node dissection.

In this study (which would include at least 200 patients over a period of 2 years, with at least 100 patients after neoadjuvant chemotherapy) the involved surgeons would continue to perform complete axillary node dissections.

The radioactive SLN would be retrieved ex vivo in the axillary piece (with the gamma probe, after intramammary and peritumoral injections of radiocolloids the day before the surgery, or at least 3 hours before, with scintigraphic preoperative images as already performed routinely for patients described in the introduction 1 of this letter). These radioactive lymph nodes would thereafter been controlled for their possible fluorescence (with our fluorescence camera and after periareolar injection of ICG in the operating room just before the surgery). Finally, in the service of Pathology, all the lymph nodes found by the pathologist in the axillary piece will be controlled for their possible fluorescence.

With this approach, the surgeon will not have to search for SLN and the operative duration will not be extended.

Secondary objectives:

The current literature about the results of SLNB technique has not yet considered the influence of the addition of SPECT-CT imaging (standard approach in our institute since more than 3 years) to planar imaging. In this study, we propose to analyse in a prospective manner the contribution of SPECT-CT: contribution of the analysis of the signal intensity of active lymph nodes on SPECT slides to define a resection threshold corresponding to lymph nodes at risk of being pN+, accuracy for the anatomic localization, better accuracy of the number of SLN on the SPECT-CT versus planar image, better definition of the number of lymph nodes (to be analysed on the CT) covered by a radioactive spot (we have already observed 3 adjacent lymph nodes under one only active spot).

In this last case, such spots covering several lymph nodes would be analysed for the possible fluorescence of each lymph node.

The fluorescence of the detected lymph nodes will be analysed semi-quantitatively and related to their pN+ characteristics (pNi, pNµ, pN1, pNmacro). This first analysis may have major implications when our surgeons will perform an in vivo research of fluorescent SLN (see also Bourgeois et al. 2003).

Finally, we propose to analyse the kinetic and the vascular characteristics (aspects of the vessels on the images) of ICG migration from its injection point to the axilla. We will try to define possible predictive parameters of extended and/or macroscopic involvement of axillary lymph nodes.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 214 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Evaluation of Near- InfraRed Imaging of ICG in Comparison With the Lymphoscintigraphic Technique Using Intramammary and Peritumoral Injection of 99mTc-HSA-Nanocolloids for the SLN Detection in BC Patients.
Study Start Date : July 2013
Estimated Primary Completion Date : October 2014
Estimated Study Completion Date : December 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Indocyanine Green
superficial injections of Indocyanine Green in the breast
Drug: Indocyanine Green
Superficial injection of ICG in combination with deep injection of 99mTc-HSA to evaluate the complementarity of the two techniques
Other Name: ICG




Primary Outcome Measures :
  1. false negative rate for each technique (fluorescence and radiocolloids) [ Time Frame: 1 week ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female patients submitted to mastectomy or tumorectomy with Complete Axillary Node Dissection (but to whose SLN procedure might be proposed in the future).
  • General operability.
  • Informed consent form signed

Exclusion Criteria:

  • Age less than18 years old.
  • Former operation in the axilla and/or breast.
  • Any previous radiotherapy at the concerned breast and/or axilla and/or chest wall.
  • History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish.
  • Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland.
  • Documented coronary disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02032498


Contacts
Layout table for location contacts
Contact: Jean-Marie Nogaret, MD 00322541 ext 3165 jeanmarie.nogaret@bordet.be
Contact: Pierre Bourgeois, MD 00322541 ext 3276 pierre.bourgeois@bordet.be

Locations
Layout table for location information
Belgium
Jules Bordet Institute Recruiting
Brussels, Belgium, 1000
Contact: Pierre Bourgeois, MD    003225413276    pierre.bourgeois@bordet.be   
Principal Investigator: Jean-Marie Nogaret, MD         
Sponsors and Collaborators
Jules Bordet Institute
Investigators
Layout table for investigator information
Principal Investigator: Jean-Marie Nogaret, MD Surgeon

Layout table for additonal information
Responsible Party: Jules Bordet Institute
ClinicalTrials.gov Identifier: NCT02032498     History of Changes
Other Study ID Numbers: 2013-001555-12
First Posted: January 10, 2014    Key Record Dates
Last Update Posted: July 24, 2014
Last Verified: July 2014
Keywords provided by Jules Bordet Institute:
sentinel lymph nodes
radiocolloids
Indocyanine Green
complementarity
axillary lymph node dissection
Additional relevant MeSH terms:
Layout table for MeSH terms
Technetium Tc 99m Aggregated Albumin
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action